New injection aims to stop cancer wasting
NCT ID NCT07237464
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new drug called GB18 in 36 healthy adults to see if it is safe and how the body handles it. The drug is designed to treat cancer cachexia, a condition where cancer patients lose weight and muscle. Participants receive a single injection of GB18 or a placebo, and researchers monitor side effects and drug levels in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GB18
- What this could lead to
- If it works, this could point toward a treatment for cancer cachexia, a condition causing severe weight loss and muscle wasting in cancer patients.
- What could go wrong
- This is a very early Phase 1 trial in healthy people, not cancer patients. It only tests safety and dosing, so it may not work for cachexia or may have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER CACHEXIA are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection stop the wasting of cancer cachexia?
- Could probiotics help breast cancer patients keep their strength?
- Fish oil and band workouts: a new hope against cancer muscle loss?
- Can rice water and eggs fight cancer wasting? new study tests cheap remedy
- New antibody aims to reverse cancer wasting
- New injection aims to fight Cancer-Related wasting